medicaid glp-1 Patients Face New Barriers for Drugs Cutting Medicaid Coverage For Weight
Description
Hundreds have answered the call so far, but the more stories we can share, the stronger our voice becomes
However, the study included a small number of participants and a shorter follow up time of only 48 weeks compared to other RCTs studying GLP-1 agonists
They're all injectable GLP-1 medications, they all work on appetite and metabolism, and they're all backed by clinical trial data
Glucagon and the glucagon-like peptides
In 2023, the average representation of GLP-1 drugs used for weight loss in employers total annual claims was 6.9%, according to survey respondents
What does this imply for clinical practice
